Expression and clinical significance of PTPN12 in clear cell renal cell carcinoma
Open Access
- 8 December 2020
- journal article
- research article
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 48 (12)
Abstract
Background: Clear cell renal cell carcinoma (ccRCC) is a common urological disease. Expression of the protein tyrosine phosphatase 12 gene ( PTPN12 ) is decreased in many cancers; however, the relationship between PTPN12 gene function and renal cancer remains unclear. Methods: We detected PTPN12 protein expression in ccRCC and corresponding normal tissues from 64 patients with ccRCC by immunohistochemistry, and relative PTPN12 mRNA levels by real-time quantitative polymerase chain reaction. The relationships between the relative expression levels of PTPN12 mRNA and the patients’ clinical data were analyzed. Results: PTPN12 protein and mRNA expression levels were significantly lower in ccRCC compared with the corresponding normal tissues. The mRNA expression levels in the ccRCC and corresponding normal tissues from the 64 patients with ccRCC were 0.459±0.445 and 1.001±0.128, respectively, compared with the control (glyceraldehyde 3-phosphate dehydrogenase). There was a significant correlation between relative expression of PTPN12 mRNA in ccRCC tissues and tumor diameter and clinical stage. Conclusion: The expression levels of PTPN12 protein and mRNA were significantly lower in ccRCC tissues compared with normal tissues. The role of PTPN12 may provide new insights and evidence to aid the diagnosis and targeted therapy of ccRCC.Keywords
This publication has 16 references indexed in Scilit:
- Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancerNature Medicine, 2018
- Immune checkpoint inhibitors in renal cell carcinomaClinical Science, 2017
- The Evolving Treatment Landscape of Advanced Renal Cell Carcinoma in Patients Progressing after VEGF InhibitionJournal of Kidney Cancer, 2017
- New treatment options for metastatic renal cell carcinomaESMO Open, 2017
- MicroRNA-194 promotes the growth, migration, and invasion of ovarian carcinoma cells by targeting protein tyrosine phosphatase nonreceptor type 12OncoTargets and Therapy, 2016
- Protein tyrosine phosphatase nonreceptor type 12 suppresses the proliferation of renal cell carcinoma by inhibiting the activity of the PI3K/mTOR pathway.2015
- Tyrosine-protein phosphatase non-receptor type 12 expression is a good prognostic factor in resectable non-small cell lung cancerOncotarget, 2015
- Decreased Expression of PTPN12 Correlates with Tumor Recurrence and Poor Survival of Patients with Hepatocellular CarcinomaPLOS ONE, 2014
- Tyrosine-Protein Phosphatase Nonreceptor Type 12 Is a Novel Prognostic Biomarker for Esophageal Squamous Cell CarcinomaThe Annals of Thoracic Surgery, 2012
- Activation of Multiple Proto-oncogenic Tyrosine Kinases in Breast Cancer via Loss of the PTPN12 PhosphataseCell, 2011